GlassScriptPhysician profile
Timothy R Peace
NPI 1245843184
$5,701.96
in general payments reported to CMS, 2019-2025
27 companies · $2,814 in 2025
The $2,814 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $128 · 2022: $218 · 2023: $733 · 2024: $1,808 · 2025: $2,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,133 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,132.53 |
| Education | $222.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,138.13 | 2022-2025 | |
| Alkermes, INC. | $671.71 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Indivior INC. | $482.87 | 2021-2025 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $468.78 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $463.06 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $372.80 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lilly USA, LLC | $234.69 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $228.26 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $220.92 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $170.84 | 2023-2025 | Spravato, Invega Sustenna |
| Almatica Pharma LLC | $159.34 | 2023-2025 | Loreev Xr, Teriparatide, Sertraline Hcl |
| Braeburn INC. | $144.43 | 2023-2025 | Brixadi |
| Lundbeck LLC | $116.25 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $113.09 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $112.52 | 2024-2025 | Cobenfy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $98.12 | 2025 | Azstarys |
| Orexo US, INC. | $85.98 | 2024-2025 | Zubsolv |
| Collegium Pharmaceutical, INC. | $85.01 | 2025 | Jornay Pm |
| Exact Sciences Corporation | $80.96 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $57.09 | 2024 | |
| Neurocrine Biosciences, INC. | $52.61 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.57 | 2022-2023 | Trintellix |
| Novo Nordisk INC | $33.26 | 2025 | Wegovy |
| Acelrx Pharmaceuticals, INC. | $20.78 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.25 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $14.46 | 2023 | Onzetra Xsail, Contrave |
| Pear Therapeutics (US), INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Peace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.